Literature DB >> 18018604

Usefulness of perioperative blood glucose control in patients undergoing off-pump coronary artery bypass grafting.

Takeshiro Fujii1, Yoshinori Watanabe, Noritsugu Shiono, Muneyasu Kawasaki, Hiroki Yokomuro, Tsukasa Ozawa, Satoshi Hamada, Hiroshi Masuhara, Nobuya Koyama.   

Abstract

OBJECTIVE: We investigated the usefulness of perioperative blood glucose control in patients undergoing coronary artery bypass grafting (CABG).
METHODS: DM patients were aggressively treated with intensive insulin therapy to achieve a preoperative fasting blood glucose level of 140 mg/dl and a postoperative level of 200 mg/dl. For comparison, patients were divided as follows: (1) DM group vs. non-DM group, and (2) for mean blood glucose level in the intensive care unit (ICU), lower than 200 mg/dl (IL) vs. 200 mg/dl or higher (IH).
RESULTS: (1) In the DM group, the amount of insulin (U) used during surgery was greater (P<0.05), and the duration of ICU stay was longer (P<0.05). The incidence of all complications was higher in the DM group (P<0.05). (2) Between the IH group (54) and the IL group (82), the proportion of DM patients was higher in the IH group (75% vs. 38%, P<0.05). In the IH, the duration of ICU stay (P<0.01) was longer, and the incidence of all complications was higher (P<0.05). (3) In the DM group, the incidence of complications tended to be higher in the IH group. The incidence of complications was extremely low in the non-DM group.
CONCLUSION: Strict perioperative blood glucose control may help to improve the outcomes of CABG.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18018604     DOI: 10.1007/s11748-007-0153-3

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  15 in total

1.  Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial.

Authors:  Patrick W Serruys; Andrew T L Ong; Lex A van Herwerden; J Eduardo Sousa; Adib Jatene; Johannes J R M Bonnier; Jacques P M A Schönberger; Nigel Buller; Robert Bonser; Clemens Disco; Bianca Backx; Paul G Hugenholtz; Brian G Firth; Felix Unger
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

2.  Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures.

Authors:  A P Furnary; K J Zerr; G L Grunkemeier; A Starr
Journal:  Ann Thorac Surg       Date:  1999-02       Impact factor: 4.330

3.  Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass.

Authors:  M J Magee; T M Dewey; T Acuff; J R Edgerton; J F Hebeler; S L Prince; M J Mack
Journal:  Ann Thorac Surg       Date:  2001-09       Impact factor: 4.330

4.  Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting.

Authors:  V H Thourani; W S Weintraub; B Stein; S S Gebhart; J M Craver; E L Jones; R A Guyton
Journal:  Ann Thorac Surg       Date:  1999-04       Impact factor: 4.330

5.  Impact of diabetes mellitus on cardiac surgery outcome.

Authors:  J Bucerius; J F Gummert; T Walther; N Doll; V Falk; J F Onnasch; M J Barten; F W Mohr
Journal:  Thorac Cardiovasc Surg       Date:  2003-02       Impact factor: 1.827

6.  Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status.

Authors: 
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

7.  Influence of diabetes mellitus on the results of coronary bypass surgery. Follow-up of 212 diabetic patients ten to 15 years after surgery.

Authors:  G M Lawrie; G C Morris; D H Glaeser
Journal:  JAMA       Date:  1986-12-05       Impact factor: 56.272

8.  Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events.

Authors:  Harold L Lazar; Stuart R Chipkin; Carmel A Fitzgerald; Yusheng Bao; Howard Cabral; Carl S Apstein
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

9.  Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.

Authors:  Anthony P Furnary; Guangqiang Gao; Gary L Grunkemeier; YingXing Wu; Kathryn J Zerr; Stephen O Bookin; H Storm Floten; Albert Starr
Journal:  J Thorac Cardiovasc Surg       Date:  2003-05       Impact factor: 5.209

10.  Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI).

Authors:  K M Detre; P Guo; R Holubkov; R M Califf; G Sopko; R Bach; M M Brooks; M G Bourassa; R J Shemin; A D Rosen; R J Krone; R L Frye; F Feit
Journal:  Circulation       Date:  1999-02-09       Impact factor: 29.690

View more
  4 in total

Review 1.  Perioperative control of blood glucose level in cardiac surgery.

Authors:  Kenji Minakata; Ryuzo Sakata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-01-05

2.  Insulin infusion on postoperative complications of coronary artery bypass graft in patients with diabetes mellitus.

Authors:  Gholamreza Masoumi; Rasoul Frasatkhish; Hamid Bigdelian; Mohsen Ziyaefard; Ali Sadeghpour-Tabae; Mojtaba Mansouri; Alireza Jalali
Journal:  Res Cardiovasc Med       Date:  2014-04-01

3.  Effects of Moderate Glycemic Control in Type II Diabetes With Insulin on Arterial Blood Gas Parameters Following Coronary Artery Bypass Graft Surgery.

Authors:  Gholamreza Masoumi; Rasoul Frasatkhish; Alireza Jalali; Mohsen Ziyaeifard; Ali Sadeghpour-Tabae; Mojtaba Mansouri
Journal:  Res Cardiovasc Med       Date:  2014-05-10

4.  Blood glucose concentration for predicting poor outcomes in patients with and without impaired glucose metabolism undergoing off-pump coronary artery bypass surgery - long-term observational study.

Authors:  Wojciech Szychta; Franciszek Majstrak; Grzegorz Opolski; Krzysztof J Filipiak
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-08-19       Impact factor: 1.426

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.